R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD)

Nephrology Dialysis Transplantation

Volumn 24, Issue 8, 2009, Pages 2371-2377

  Moe, Sharon M ^a,b   Seifert, Mark F ^a   Chen, Neal X ^a   Sinders, Rachel M ^a   Chen, Xianming ^a   Duan, Dana ^a   Henley, Charles ^c   Martin, Dave ^c   Gattone, Vincent H ^a  

^a INDIANA UNIVERSITY   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c AMGEN INC   (United States)

Author keywords

Kidney; Mineral bone disorder; Parathyroid hormone; Renal osteodystrophy; Vascular calcification

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM; PHOSPHORUS; R 568; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL FOOD; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL MODEL; BONE MINERAL; CALCIFICATION; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY DISEASE MINERAL BONE DISORDER; CONTROLLED STUDY; DIET; DRUG EFFICACY; DRUG MECHANISM; MALE; MORPHOMETRICS; NONHUMAN; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RAT; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM;

ANILINE COMPOUNDS; ANIMALS; CALCINOSIS; CALCIUM; DISEASE MODELS, ANIMAL; HYPERPARATHYROIDISM; MALE; MINERALS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RATS; RATS, SPRAGUE-DAWLEY; RENAL OSTEODYSTROPHY;

EID: 67649732072     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp078     Document Type: Article

References (28)

1. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953
2. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38
3. Barreto FC, Barreto DV, Moyses RM et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 2008; 73: 771-777
4. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824
5. Mehrotra R, Adler S. Coronary artery calcification in nondialyzed patients with chronic kidney diseases. Am J Kidney Dis 2005; 45: 963
6. Baker LR, Abrams L, Roe CJ et al. 1, 25 (OH)2D3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int 1989; 35: 661-669
7. Baker LR, Abrams SM, Roe CJ et al. Early therapy of renal bone disease with calcitriol: a prospective double-blind study. Kidney Int Suppl 1989; 27: S140-S142
8. Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol 2006; 1: 697-703
9. Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005; 67: 760-771
10. Chertow GM, Pupim LB, Block GA et al. Evaluation of cinacalcet therapy to lower cardiovascular events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2007; 2: 898-905
11. Charytan C, Coburn JW, Chonchol M et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 2005; 46: 58-67
12. Moe SM, Chen NX, Seifert M et al. A rat model of chronic kidney disease-mineral bone disorder (CKD-MBD) and the effect of dietary protein source. Kidney Int 2009; 75: 176-184
13. Kaspareit-Rittinghausen J, Deerberg F, Wcislo A. Hereditary polycystic kidney disease. Adult polycystic kidney disease associated with renal hypertension, renal osteodystrophy, and uremic enteritis in SPRD rats. Am J Pathol 1991; 139: 693-696
14. Brown JH, Bihoreau MT, Hoffmann S et al. Missense mutation in sterile alpha motif of novel protein SamCystin is associated with polycystic kidney disease in (cy/+) rat. J Am Soc Nephrol 2005; 16: 3517-3526
15. Gattone VH, II, Chen NX, Sinders RM et al. Calcimimetic inhibition of late stage renal cystic pathology in a rat model of autosomal dominant polycystic kidney disease. In press, J Am Soc Nephrol 2009
16. Hjorth-Hansen H, Seifert MF, Borset M et al. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res 1999; 14: 256-263
17. Parfitt AM, Drezner MK, Glorieux FH et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987; 2: 595-610
18. Olgaard K, Lewin E. Prevention of uremic bone disease using calcimimetic compounds. Annu Rev Med 2001; 52: 203-220
19. Brown EM, Chattopadhyay N, Yano S. Calcium-sensing receptors in bone cells. J Musculoskelet Neuronal Interact 2004; 4: 412-413
20. Wada M, Ishii H, Furuya Y et al. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 1998; 53: 448-453
21. Malluche HH, Monier-Faugere MC, Wang G et al. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 2008; 69: 269-278
22. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007
23. Pletcher MJ, Tice JA, Pignone M. Use of coronary calcification scores to predict coronary heart disease. JAMA 2004; 291: 1831-1832; author reply 2-3
24. London GM, Marty C, Marchais SJ et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951
25. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252
26. Lopez I, Aguilera-Tejero E, Mendoza FJ et al. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 2006; 17: 795-804
27. Lopez I, Mendoza FJ, Aguilera-Tejero E et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008; 73: 300-307
28. Neves KR, Graciolli FG, dos Reis LM et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 2007; 71: 1262-1270